Needham & Company LLC Reaffirms Buy Rating for Merit Medical Systems (NASDAQ:MMSI)

Merit Medical Systems (NASDAQ:MMSI)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a report released on Wednesday,Benzinga reports. They currently have a $101.00 target price on the medical instruments supplier’s stock. Needham & Company LLC’s price objective would indicate a potential upside of 49.19% from the stock’s current price.

Several other equities analysts also recently commented on MMSI. Wall Street Zen upgraded Merit Medical Systems from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 28th. Canaccord Genuity Group upped their price objective on shares of Merit Medical Systems from $93.00 to $99.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Barrington Research raised their target price on shares of Merit Medical Systems from $106.00 to $109.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Weiss Ratings reissued a “hold (c)” rating on shares of Merit Medical Systems in a research report on Friday, March 27th. Finally, Piper Sandler decreased their price target on shares of Merit Medical Systems from $113.00 to $106.00 and set an “overweight” rating for the company in a report on Wednesday, February 18th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Merit Medical Systems has an average rating of “Moderate Buy” and a consensus price target of $101.25.

Merit Medical Systems Price Performance

Shares of NASDAQ:MMSI opened at $67.70 on Wednesday. The stock has a market capitalization of $4.04 billion, a P/E ratio of 31.93, a P/E/G ratio of 1.97 and a beta of 0.64. The business has a 50-day moving average of $75.70 and a two-hundred day moving average of $81.71. Merit Medical Systems has a fifty-two week low of $66.34 and a fifty-two week high of $106.11. The company has a debt-to-equity ratio of 0.46, a current ratio of 4.34 and a quick ratio of 2.95.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings data on Tuesday, February 24th. The medical instruments supplier reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.08. Merit Medical Systems had a return on equity of 13.82% and a net margin of 8.48%.The business had revenue of $393.94 million for the quarter, compared to analyst estimates of $390.77 million. During the same quarter in the prior year, the firm posted $0.93 EPS. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. On average, equities research analysts predict that Merit Medical Systems will post 3.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Tudor Investment Corp ET AL acquired a new stake in Merit Medical Systems during the third quarter worth $2,913,050,000. Wellington Management Group LLP raised its stake in shares of Merit Medical Systems by 377.7% in the 3rd quarter. Wellington Management Group LLP now owns 1,240,509 shares of the medical instruments supplier’s stock valued at $103,248,000 after buying an additional 980,823 shares in the last quarter. Norges Bank acquired a new position in shares of Merit Medical Systems in the 4th quarter valued at $75,957,000. Thrivent Financial for Lutherans lifted its holdings in shares of Merit Medical Systems by 250.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 750,066 shares of the medical instruments supplier’s stock worth $62,428,000 after acquiring an additional 536,072 shares during the period. Finally, Iron Triangle Partners LP bought a new position in Merit Medical Systems during the fourth quarter worth about $33,992,000. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Merit announced the acquisition of View Point Medical for approximately $140 million, adding the OneMark® Detection Imaging System and tissue markers to its oncology/localization portfolio. Management projects $14–$16M revenue contribution in 2027, high gross margins, and strategic fit with Merit’s SCOUT® platform — a clear growth catalyst for its therapeutic oncology franchise. Merit Medical acquires imaging oncology company View Point Medical for $140M
• Positive Sentiment: Sell‑side support remains: Needham reaffirmed a Buy rating with a $101 price target and several analysts maintain targets well above the current level (median ~$103.5), which underpins upside expectations if integration and growth targets are met. Analyst coverage and price targets
• Neutral Sentiment: Merit will report Q1 2026 results after the close on April 30 and host an investor call that day — an event likely to drive short‑term volatility as the market digests organic trends and acquisition impacts. Webcast and slides will be available on the company site. Merit Medical to Announce First Quarter 2026 Results on April 30, 2026
• Negative Sentiment: Near‑term earnings dilution and cash use: Merit estimates the View Point deal will contribute only $2–$4M in 2026 and dilute non‑GAAP EPS by ~ $0.05 in 2026 (plus transaction costs), and be GAAP‑dilutive through 2027 — a common reason for downward pressure until accretion materializes. Merit Medical acquires View Point (press release)
• Negative Sentiment: Insider and institutional selling: public filings show multiple insider sales in recent months and large institutional rebalancing (several big funds reduced positions), which can increase selling pressure and weigh on the stock while liquidity is lighter than average. QuiverQuant summary including insider and institutional activity

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.